【#宝宝异常嗜睡体内查出安眠药成分#】#警方介入宝宝体内查出安眠药成分# 近日，浙江永康的徐女 士发帖称自己9个月大的宝宝被育儿嫂下药。徐女士称，育儿嫂上户一个月后宝宝变得异常嗜睡、奶量 减少，身上还长红疹，带宝宝去医院检查后，血检、尿检都被检查出"唑吡坦"成分（唑吡坦是一种短效 镇静催眠药，主要用于严重失眠的短期治疗，被列为第二类精神药品管控）。2026年1月2日，徐女士告 诉潇湘晨报记者，她在永康可依家政公司以7600元/26天价格请了一位育儿嫂，她表示，2025年12月30 日晚上，自己家龙凤胎男宝昏睡不醒，她与家人察觉异常后报警，并带宝宝去医院检查，发现体内有安 眠药成分。徐女士称，事发后育儿嫂不承认"下药"行为，并表示自己"问心无愧"，目前，育儿嫂已被警 方带走调查，徐女士说，自己一定会追究到底，已在联系律师。对此，永康可依家政公司负责人表 示，"不清楚具体情况，警方已介入调查，自己也在等结果"，并表示育儿嫂向她透露，徐女士宝宝因为 生病一直在吃药。徐女士称，宝宝因为尿道畸形在吃小剂量的阿莫西林，"不可能接触到思诺思这种管 控药物"。（潇湘晨报） ...

（来源：千龙网） 在经历两次住院之后，林可决定戒断普瑞巴林。 这是一款原本用于治疗神经性疼痛的处方药。她曾一次性吞下20多片普瑞巴林，试图用药物迅速压住体 内的焦虑、恐惧和失控感——"让自己暂时不用面对现实"。 随后，她被送进急诊。凌晨两点，林可躺在病房的床上，盯着天花板，已经70多个小时没有合眼。这是 林可今年夏天第二次因为滥用普瑞巴林住院，距离上一次，只隔了一个月。第一次是在8月，她的心率 飙升到每分钟150次，晕倒在路上被室友送进急诊，那次也吃了20几片。 此前，林可还过量服用右美沙芬等多种药物。后来，右美沙芬被列管，购买变得困难，普瑞巴林成 为"替代品"。 林可的经历并非个案。近段时间，我国陆续出现普瑞巴林滥用的病例报告。2025年3月，湖南省脑科医 院在国际期刊《精神病学前沿》发表一则病例报告，记录了一名患者在长期、大剂量滥用普瑞巴林后形 成依赖。其中提到，此前，中国尚未报告过普瑞巴林依赖病例。 2025年4月，《中国药物依赖性杂志》发表一则由山东省药品不良反应监测中心报告的病例，一位既往 有滥用右美沙芬病史的未成年患者，在右美沙芬列管后，开始使用其他药物替代滥用，其中普瑞巴林获 得最为便利，替代使 ...

Core Insights - The article highlights the increasing prevalence of depression in China, with approximately 95 million individuals affected, leading to a booming market for antidepressant medications [5][12][18] - The demand for antidepressants has surged, with sales in public medical institutions exceeding 9.1 billion yuan in the previous year, marking a 6% year-on-year increase [5][7] - The market for antidepressants is becoming increasingly competitive, with numerous domestic pharmaceutical companies entering the space, particularly in the production of generic drugs [13][20] Market Dynamics - The rise in depression cases has created a vibrant pharmaceutical market, with companies like Hansoh Pharmaceutical and Jingwei Pharmaceutical achieving significant sales figures [7][12] - The sales of antidepressants in public hospitals have seen a drastic shift, with domestic companies gaining market share due to price reductions and increased competition [22][24] - The introduction of centralized procurement has led to a significant drop in drug prices, making antidepressants more accessible to patients [19][20][22] Industry Challenges - Despite the growing market, the high cost of psychological therapy remains a barrier for many patients, leading to a preference for medication over therapy [26][27] - The perception of antidepressants as a long-term necessity poses challenges for patient management, with many experiencing withdrawal symptoms when discontinuing medication [26][27] - The industry faces scrutiny over the quality of psychological counseling services, which can vary significantly, impacting patient experiences and outcomes [26][27]

Core Insights - The article highlights the increasing prevalence of depression in China, with approximately 95 million individuals affected, leading to a booming market for antidepressant medications [4][6]. - The demand for antidepressants has surged, with sales in public medical institutions exceeding 9.1 billion yuan in the previous year, marking a 6% year-on-year increase [4][6]. - The article discusses the shift in societal attitudes towards mental health, with more individuals seeking treatment and awareness growing, particularly among younger generations [10][12]. Market Dynamics - The pharmaceutical companies, such as Hansoh Pharmaceutical and Jingwei Pharmaceutical, have seen significant sales growth, with Jingwei's escitalopram generating 700 million yuan in revenue [6]. - The competitive landscape for antidepressants is intensifying, with over 40 generic antidepressants approved for sale in China this year alone, and at least 32 new antidepressant drugs in various stages of clinical approval [13][12]. - The article notes a shift in market dynamics due to price reductions from collective procurement, which has led to a decrease in sales revenue despite an increase in the volume of antidepressant prescriptions [20][22]. Patient Experience and Treatment - The article emphasizes the long-term nature of depression treatment, with many patients requiring ongoing medication, which can lead to withdrawal symptoms if abruptly stopped [29][31]. - The high cost of psychological therapy remains a barrier for many patients, leading to a preference for medication over therapy despite the need for a comprehensive treatment approach [31][32]. - The narrative includes personal accounts of individuals struggling with depression, illustrating the emotional and financial burdens associated with treatment [25][32]. Industry Challenges - The article points out the challenges faced by the industry, including the high barriers to developing new CNS drugs and the slow pace of innovation in antidepressant options [17][19]. - It also highlights the potential pitfalls of a saturated market, where the influx of generic drugs may not necessarily translate to profitability for all companies involved [14][23]. Societal Impact - The article discusses the broader societal implications of rising depression rates, suggesting that as society becomes more affluent, mental health issues are more likely to be recognized and addressed [11][12]. - It notes the importance of community mental health initiatives and public awareness campaigns in changing perceptions and encouraging individuals to seek help [10][11].

Core Viewpoint - The article discusses the growing market for antidepressant medications in China, driven by an increasing number of patients suffering from depression and the rising acceptance of mental health treatment [5][14][28]. Group 1: Market Dynamics - The total number of individuals with depression in China has reached 95 million, with approximately 38 million registered patients as of 2023, leading to a booming pharmaceutical market [6][7]. - Sales of antidepressant medications in public medical institutions reached a record high of over 9.1 billion yuan in the previous year, marking a 6% year-on-year growth [6]. - The demand for antidepressants has led to significant sales increases for companies like Hansoh Pharmaceutical, which ranks among the top three in the antidepressant market, and Green Leaf Pharmaceutical, whose new drug saw a 99.9% sales surge [7][8]. Group 2: Changing Perceptions and Treatment - There is a noticeable shift in societal attitudes towards mental health, with more individuals, especially the younger generation, actively seeking treatment for depression [14][11]. - The stigma surrounding mental health issues is gradually diminishing, allowing for greater awareness and acceptance of conditions like depression [14][11]. - The article highlights the importance of early detection and intervention in managing depression, although many patients still face barriers to seeking help [11][14]. Group 3: Competitive Landscape - The number of companies producing generic antidepressants has increased significantly, with over 40 generic antidepressants approved for sale this year alone [15][16]. - The competitive landscape is intensifying, with domestic companies aggressively entering the market, leading to price reductions for antidepressant medications [25][28]. - The introduction of centralized procurement has further driven down prices, making medications more accessible to patients [26][28]. Group 4: Challenges in Treatment - Despite the growing market, many patients still struggle with the high costs of original branded medications, which can consume a significant portion of their income [21][22]. - The article notes that the development of new antidepressants is slow due to high research and development barriers, leading to a relatively stable market for existing medications [22][24]. - The perception of antidepressants as "addictive" is discussed, with experts clarifying that withdrawal symptoms are often misinterpreted as addiction [33][34]. Group 5: Future Outlook - The article suggests that as more patients seek treatment and the market continues to evolve, the demand for antidepressants will likely remain strong, despite current market fluctuations [29][30]. - The ongoing changes in pricing and market dynamics may lead to a more sustainable and accessible treatment landscape for patients suffering from depression [28][29].

因此，对二类精神药品的管制力度较为薄弱，既会从源头导致"药品变毒品"的风险，也让缺乏相关 知识的患者在药物剩余后，可能面临处置不当的法律风险。但也需要看到，以思诺思为例的安眠药，不 少患者需要长期服用、频繁开药，医生出于对患者病情和用药便利性的考量，超量开药常常难以避免。 因此，加强对重点领域医务人员教育管理的同时，或可以更严格且成文的机制适当允许特批增加处方 量，让"超量开具"更规范、有据可依。 另外，我国目前仅对一类精神药品的交回做出规定，也应当建立对二类精神药品的回收渠道。有关 麻醉药品、一类精神药品的交回规定中提到，医疗机构应当要求患者将剩余的有关药品无偿交回医疗机 构，并由医疗机构按照规定销毁处理。对于二类精神药品，不妨以奖励性措施鼓励患者主动交回剩余药 品，既提高公众交回的积极性，也有助于增强公众对精神药品的风险意识。 马某的案件虽未正式落槌，但也有必要对类似事件进行反思，国家管制药品的规范流通需要"既不 放过也不错抓"。当前，随着新型毒品和新型精神药品的出现，毒品犯罪也呈现出新的趋势，除了执法 环节要从严查处，从源头完善的药品开具规范和回收机制也必不可少。保证患者用药便利与安全、防范 药品变毒品 ...

会上，有记者问，发布的典型案例中有多个案例麻精药品来自正规渠道，如医院、诊所、医药公司 等，人民法院在依法惩处的同时，如何有效预防此类涉医疗麻精药品犯罪发生？ 中新网6月23日电 最高人民法院23日举行人民法院禁毒工作情况新闻发布会。最高人民法院刑五庭 副庭长李晓光在会上表示，人民法院高度重视治理医疗用麻精药品流弊问题，坚持治罪与治理并重。 李晓光介绍，在治理层面，延伸审判职能，促推源头治理、综合治理。一方面，加强宣传教育，让 社会公众充分认识到"医疗用麻精药品滥用也是毒品"，切实增强群众安全用药意识。我也借此机会呼 吁，即便是治疗疾病服用麻精药品，也要严格遵照医嘱，不能滥用；对于闲置的此类药品，也不要贪图 小利随意处置。另一方面，人民法院用好制发司法建议等手段，会同有关部门查漏补缺，建章立制，构 建更为严密完善的麻精药品监管体系。 近年来，人民法院高度重视治理医疗用麻精药品流弊问题，坚持治罪与治理并重，在治罪与治理两 个层面双向发力，标本兼治。在治罪层面，立足审判职能，做好案件审理，确保案件定性准确、罚当其 罪。2023年4月、6月，最高人民法院先后印发《关于进一步加强涉麻醉药品和精神药品案件审判工作的 通 ...